UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the six months ended June 30, 2022
Commission File No. 001-41010
MAINZ BIOMED N.V.
(Translation of registrant’s name into English)
Robert Koch Strasse 50
55129 Mainz
Germany
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) ☐
Other Events
On September 7, 2022, Mainz BioMed N.V. made available its Management’s
Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2022. A copy of the
report is attached hereto as Exhibit 99.1.
On September 7, 2022, Mainz BioMed N.V. made available its Half-Year
Statements for the six months ended June 30, 2022. A copy of the report is attached hereto as Exhibit 99.2.
Furnished as Exhibit 99.3 to this Report on Form 6-K is a press release
of Mainz BioMed N.V. (the “Company”) dated September 7, 2022, announcing the Company’s results for the six months ended
June 30, 2022.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: September 7, 2022 |
By: |
/s/ William J. Caragol |
| |
Name: |
William J. Caragol |
| |
Title |
Chief Financial Officer |
2